Soleno Therapeutics Inc (SLNO)

[BioSpecialist]

SLNO(Market-Cap $19 M) Potential Blockbuster Drug in Phase 3 .. I really really like this one especially because of its dirt low valuation of $19 Million and the huge potential of the Drug .This is a strong buy aggressive at this ridiculous price .Fair Value for a such company should be $4-6 and much higher with positive Phase 3 results which expected by end 2018 .GL


Initiating Coverage June 26, 2017
http://www.lifescicapital.com/wp-content/uploads/Soleno.pdf

•Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete


Market Opportunity for PWS is Substantial.

While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE)
Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.



Very Strong Insider & institutional Ownership:

Vivo Ventures LLC 16 012 808
Forward Ventures Services LLC 7 251 728
Technology Partners 7 050 691
Aspire Capital Partners LLC 2 791 666
Ernest Mario, PhD 1 844 328
Oppenheim Asset Management Services SARL 574 853
Medical Strategy GmbH 503 305
Palo Alto Investors LLC 423 738
Sabby Capital LLC 233 938
The Bollard Group LLC 192 217